Indications |
Oral Acute pain Adult: 100 mg bid. Use in the European Union (EU) is limited to a max of 15 days. Oral Dysmenorrhoea Adult: 100 mg bid. Use in the European Union (EU) is limited to a max of 15 days. Oral Osteoarthritis Adult: 100 mg bid. Use in the European Union (EU) is limited to a max of 15 days. Oral Postoperative pain Adult: 100 mg bid. Use in the European Union (EU) is limited to a max of 15 days. Rectal Acute pain Adult: 200 mg bid Rectal Osteoarthritis Adult: 200 mg bid Rectal Primary dysmenorrhoea Adult: 200 mg bid Topical/Cutaneous Sprains Adult: 3% gel/cream: Apply thin layer to affected area bid-tid. Duration: 7-15 days. Topical/Cutaneous Acute traumatic tendinitis Adult: 3% gel/cream: Apply thin layer to affected area bid-tid. Duration: 7-15 days. |
Contraindications |
Hypersensitivity; GI bleeding, active peptic ulcer disease; severe renal and heart failure; hepatic impairment or known liver disease; coagulation disorders; pregnancy; children <12 yr. |
Warnings / Precautions |
History of GI tract disease, infections, oedema, hypertension, elderly, lactation. |
Adverse Reactions |
Epigastric discomfort, heartburn or abdominal cramps, nausea, vomiting and diarrhoea; skin rash, pruritus, oedema, headache, dizziness, drowsiness; hypersensitivity reactions (e.g. bronchospasm, rhinitis, angioedema urticaria); GI haemorrhage/perforation; bullous/erosive stomatitis, purpura, thrombocytopenia, toxic epidermal necrolysis, haematuria, oliguria, and renal failure; increases in liver enzymes. Potentially Fatal: Fatal hepatitis, Stevens Johnson syndrome. |
Overdose Reactions |
Epigastric pain, nausea, vomiting, drowsiness, lethargy, GI haemorrhage, seizures, hypertension, apnoea, coma, anaphylactic reactions and renal failure. Treatment is supportive. |
Drug Interactions |
Additive hepatotoxic effects with known hepatotoxins: anti-convulsants (e.g. valproic acid), anti-fungals (e.g. ketoconazole), anti-tuberculous drugs (e.g. isoniazid), tacrine, pemoline, amiodarone, methotrexate, methyldopa, amoxicillin/clavulanic acid. May decrease the oral bioavailability of furosemide and the natriuretic and diuretic response to furosemide. Increased risks of GI and hepatic adverse effects with other NSAIDs, including aspirin. May increase anti-coagulant effect of warfarin. Potentiates the action of phenytoin. May be displaced from binding sites with fenofibrate, salicylic acid, and tolbutamide. Interactions between NSAIDs and lithium, probenecid and ciclosporin, have been documented. See Below for More nimesulide Drug Interactions |
Food Interactions |
Alcohol increases the risk of hepatic reactions. |
Mechanism of Actions |
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, anti-pyretic, and analgesic properties. It inhibits prostaglandin synthetase/cyclooxygenase, which limits prostaglandin production. Its cyclooxygenase inhibiting potency is intermediate, but is relatively selective for the cyclo-oxygenase-2 (COX-2) thus the potential for gastric injury and intolerance is less. It is also a free radical scavenger, and helps protect against the tissue damage that occurs during inflammation. Absorption: Well absorbed from GI tract following oral admin. Peak plasma levels:1-3 hr. With bid admin of 100 mg, steady-state is achieved within 24-36 hr. Distribution: 99% bound to plasma protein. Metabolism: Hepatic biotransformation; principal metabolite is 4-hydroxy-nimesulide. Excretion: Elimination half-life: 2-5 hr. Metabolites in urine: 80%, feces: 20% of the administered dose.9% bound to plasma protein. |
Administration |
Should be taken with food. (Take after meals.) |
Storage Conditions |
Oral: Protect from heat and humidity; store at <25°C. |
ATC Classification |
M01AX17 - nimesulide ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products. |
Storage |
Oral: Protect from heat and humidity; store at <25°C. |
Available As |
|
Nimesulide
Post Review about Nimesulide Click here to cancel reply.
Nimesulide Containing Brands
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.